BioXcel Therapeutics (NASDAQ:BTAI) hosted a key opinion leader (KOL) virtual roundtable focused on acute agitation episodes in Alzheimer’s dementia, highlighting what participants described as a major unmet need for patients, caregivers, and clinicians. CEO Vimal Mehta opened the event by emphasizing that there are currently no FDA-approved treatments specifically for acute episodes of agitation in […]